The Dutch Competition Authority requires a pharmaceutical producer of TNF inhibitor to waive quantity conditions on its discounts to purchasing hospitals (Pfizer)

The Dutch competition authority today announced, and at the same time closed, a case concerning pricing strategies against biosimilar competitors. The case concerns the product Enbrel (etanercept - a TNF inhibitor use for treatment of autoimmune diseases), and

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The Dutch Competition Authority requires a pharmaceutical producer of TNF inhibitor to waive quantity conditions on its discounts to purchasing hospitals (Pfizer), 11 February 2022, e-Competitions February 2022, Art. N° 105390

Visites 195

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues